vVARDIS $175 million IPO
We are advising vVARDIS on its IPO and NYSE listing
Davis Polk is advising vVARDIS Holding AG on its SEC-registered initial public offering of 9,722,223 Class A ordinary shares at $18.00 per Class A ordinary share for total gross proceeds of $175 million. The underwriters have a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares from vVARDIS. The Class A ordinary shares are listed on the New York Stock Exchange under the ticker symbol “VVVV.”
vVARDIS is a Swiss healthcare company in the dental med-tech sector headquartered in Zug, Switzerland, that offers innovative, non-invasive solutions for dental professionals with the Curodont brand of products. Founded in Switzerland by Dr. Haley Abivardi and Dr. Goly Abivardi – internationally renowned dentists and serial entrepreneurs – with a vision to improve overall health globally by defining and establishing a new category in oral health, vVARDIS’ mission is to create a world where cavity treatment is drill-free, regenerative and accessible to all.
The Davis Polk capital markets team includes partners Yasin Keshvargar and Deanna L. Kirkpatrick, counsel Maxim Van de moortel and associates Ryan Mainous and Jack Turner. Partner Amanda Hines Gold and associate Long Shi are providing executive compensation advice. Partner David R. Bauer is providing intellectual property advice. Partner Corey M. Goodman and counsel Tracy L. Matlock are providing tax advice. Members of the Davis Polk team are based in the New York and London offices.